Tuesday, February 25, 2020 NIH Clinical Trial of Remdesivir to Treat COVID-19 Begins NIH has begun a clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir in hospitalized adults diagnosed with COVID-19. The trial has enrolled a participant at the University of Nebraska Medical Center (UNMC) in Omaha. The study can be adapted to evaluate additional investigative treatments and to enroll participants at other sites in the U.S. and worldwide. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107